Drug Criteria & Outcomes: Drugs In the Pipeline
Drug Criteria & Outcomes
In the Pipeline
• Myriad Genetics reports that it has begun preclinical testing of its anti-thrombin III drug (MPC-1203). The drug is used for the treatment of acute thrombotic events such as those due to inflammation following major trauma, orthopedic or open-heart surgery, as well as for the prevention of blood clotting due to sepsis and cancer.
• SciClone Pharmaceuticals announces it has initiated a Phase II trial combining the company’s immune system enhancer (Zadaxin) with transarterial chemoembolization in patients with hepatocellular carcinoma. A Phase II trial also was initiated in January that combined the drug with radio frequency ablation.
• Scios announces that that the Cardiovascular and Renal Drugs Advisory Committee to the FDA has unanimously recommended approval of nesiritide (Natrecor) for the treatment of acute congestive heart failure by a vote of 10-0. If approved by the FDA, Natrecor would be the first new treatment for acute CHF in more than a decade.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.